NDC 81033-015-05 - NYSTATIN
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 81033-015
- Requested NDC
- 81033-015-05
- Package NDCs from labels
- 81033-015-16, 81033-015-60, 81033-015-05, 81033-015-01, 81033-015-54
- Manufacturer
- Kesin Pharma Corporation
- Effective date
- 2026-06-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NYSTATIN - Kesin Pharma Corporation | Kesin Pharma Corporation | 2026-06-30 | HUMAN PRESCRIPTION DRUG LABEL |
| NYSTATIN - Kesin Pharma Corporation | Kesin Pharma Corporation | 2025-12-11 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 81033-015-01 | NYSTATIN | 100 in 1 CASE | SUSPENSION | 100 | 2 | |
| 81033-015-05 | NYSTATIN | 5 mL in 1 CUP, UNIT-DOSE | SUSPENSION | 5 | 2 | |
| 81033-015-54 | NYSTATIN | 50 in 1 CARTON | SUSPENSION | 50 | 2 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 81033-015-01 | ML - Milliliter | 81033-015 | 2cfb8a81-2eb0-4024-8476-284f8d063336 | 1 | 2026-03-17 |
| 81033-015-05 | ML - Milliliter | 81033-015 | 49867bf3-a8d3-4975-bb87-7df548767592 | 1 | 2026-03-17 |
| 81033-015-54 | ML - Milliliter | 81033-015 | 24ab3546-05de-4da6-a3a5-dadae4b1265b | 1 | 2026-03-17 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Optimel Manuka Forte Eye Gel | GLYCERIN | Melcare Biomedical Pty Ltd | 8e0ed6e8-51fc-7c5b-e053-2a95a90a35a9 | 2026-03-11 | Warnings | PDC6A3C0OX |
| SODIUM PHOSPHATES | SODIUM PHOSPHATES | Caplin Steriles Limited | 46de992b-5fc8-4dad-8d95-77938decb67e | 2026-03-10 | Warnings, Adverse reactions | 70WT22SF4B 593YOG76RN |
| Fleet | GLYCERIN | C.B. Fleet Company, Inc. | 31778652-e60e-4098-8e90-3e4f56b5800c | 2026-03-06 | Warnings | PDC6A3C0OX |
| Glycerin | GLYCERIN | Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd | 4c6094b7-c1ef-26a3-e063-6394a90af4cc | 2026-03-06 | Warnings | PDC6A3C0OX |
| Artificial Tears | GLYCERIN | Preferred Pharmaceuticals Inc. | dd646c72-8f47-43c6-a734-db0dcc8cd4d1 | 2026-03-06 | Warnings | PDC6A3C0OX |
| Nystatin | NYSTATIN | Chartwell RX, LLC | 9954118e-abe6-4388-98c9-4473d39b2e28 | 2026-03-05 | Adverse reactions | 312055 BDF1O1C72E |
| Dry Eye Relief Sterile Lubricant Eye Drops | GLYCERIN | Similasan Corporation | 4c4cce1c-392e-354d-e063-6294a90a0ca3 | 2026-03-05 | Warnings | PDC6A3C0OX |
| Nystatin and triamcinolone acetonide | NYSTATIN AND TRIAMCINOLONE ACETONIDE | NuCare Pharmaceuticals, Inc. | 4c122a83-a66a-15d6-e063-6294a90acfaa | 2026-03-02 | Adverse reactions | BDF1O1C72E |
| Sore Throat | PHENOL GLYCERIN | CVS PHARMACY, INC | 9683bcfb-2f7e-48a4-aa79-500ee8df099a | 2026-03-02 | Warnings | PDC6A3C0OX |
| Refresh Optive Mega-3 PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | 326cb5d6-c784-404f-9a13-6d69262dda6e | 2026-03-01 | Warnings | PDC6A3C0OX |
| Nystatin | NYSTATIN | Cardinal Health 107, LLC | d59098da-1395-49fb-9fd6-947bbbeed56f | 2026-02-26 | Adverse reactions | 312055 BDF1O1C72E |
| Dermatool Hemorrhoidal | GLYCERIN, LIDOCAINE, PETROLATUM, PHENYLEPHRINE HCL | Papalo Group LLC | 4bc06f41-7733-ebd0-e063-6294a90af7a8 | 2026-02-26 | Warnings | PDC6A3C0OX |
| BM BIO28 (General Tonic) | CALC SULPH, CALC FLUOR, CALC PHOS, FERR PHOS, KALI MUR, KALI PHOS, KALI SULPH, MAG PHOS, NAT PHOS, NAT SULPH, NAT MUR, SILICEA | BM Private Limited | 38d2cff0-3550-b119-e063-6394a90a31cb | 2026-02-23 | Warnings | 70WT22SF4B |
| Nystatin | NYSTATIN | Major Pharmaceuticals | 17b9e33d-da9c-467a-bbc4-9e257727f19a | 2026-02-23 | Adverse reactions | 312055 BDF1O1C72E |
| BIO COM 25 ACIDITY | NAT PHOS, NAT SULPH, SILICEA | BM Private Limited | 3b3c3455-b321-071d-e063-6394a90a0160 | 2026-02-17 | Warnings | 70WT22SF4B |
| WowDay Hemorrhoid and Fissure Cream | HEMORRHOID AND FISSURE CREAM | WowDay LLC | 47ba86ad-240a-e733-e063-6394a90a24e3 | 2026-02-12 | Warnings | PDC6A3C0OX |
| Viva Hydration Boost | GLYCERIN | Nomax Inc | 174193b2-65eb-b5fd-e063-6394a90a9cd0 | 2026-02-10 | Warnings | PDC6A3C0OX |
| Nystatin Oral Suspension | NYSTATIN | Xttrium Laboratories, Inc. | 4a670371-d373-1ba6-e063-6394a90a13b6 | 2026-02-06 | Adverse reactions | 312055 BDF1O1C72E |
| Optase | GLYCERIN | Scope Health Inc | 376e0289-28e9-e87f-e063-6294a90a3b04 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 10c3e31d-779d-8ff6-e063-6294a90acd39 | 2026-01-30 | Warnings | PDC6A3C0OX |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.